Become an Industry Collaborator
AbbVie
Company Website
AstraZeneca
Company WebsiteBioNTech
Company Website
Corcept Therapeutics
Company WebsiteWe’ve been unlocking the potential of cortisol modulation for more than 25 years.
We’re leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators.
In 2012, we received FDA approval of Korlym® (mifepristone), the first approved treatment for hypercortisolism (Cushing syndrome).
Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat serious diseases. With more than 30 ongoing studies across a wide range of disease areas, including endocrinology, oncology, metabolism, and neurology, we remain dedicated to advance the possibilities of cortisol modulation.
What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease.
Eisai
Company WebsiteEisai Inc. is a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases).
GENENTECH
Company WebsiteGenentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. Genentech manufactures and commercializes several major oncology drugs include Herceptin, Rituxan, Avastin and Tarceva.
Genmab
Company WebsiteGenmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
GSK
Company WebsiteGSK is focused on maximizing patient survival through transformational medicines. GSK’s oncology pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination.
GILEAD
Company WebsiteGilead and Kite Oncology are creating the future of oncology. Making bold strides against cancer requires a strategy built on the power of partnerships, groundbreaking technologies and unexpected clinical combinations. We have purposefully built our pipeline with a focus on depth and breadth to address the greatest unmet needs. From antibody-drug conjugates and small molecules to cell therapy-based approaches, our research and development programs are creating possibilities for people with overlooked, underserved, and difficult-to-treat cancers. We are focused on helping to bring more life to people with cancer and changing the way cancer is treated.
Karyopharm Therapeutics
Company WebsiteKaryopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical conditions.
Our company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with cancer and other serious diseases.
Our novel approach to cancer treatment involves targeting the export of specific proteins in a cancer cell’s nucleus with SINE technology (Selective Inhibition of Nuclear Export).
Our primary focus is on developing novel drugs which we hope will help treat patients with certain blood cancers or solid tumor malignancies.
Lilly
Company WebsiteEli Lilly and Company is a leading innovation-driven corporation and is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs.
Lilly Oncology is committed to providing comprehensive healthcare solutions – answers that matter – for oncologists and cancer patients around the world through the discovery and development of breakthrough cancer medicines.
Natera
Company Website
OncoC4
Company WebsitePfizer Oncology
Company WebsiteOur Purpose: We’re in relentless pursuit of breakthroughs that change patients’ lives. We innovate every day to make the world a healthier place. It was Charles Pfizer’s vision at the beginning and it holds true today.
SUTRO BIOPHARMA
Company WebsiteDedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need. To date, Sutro’s platform has led to ADCs, bispecific antibodies, cytokine-based immuno-oncology therapies, and vaccines directed at precedented targets in clinical indications where the current standard of care is suboptimal.
Toray Industries, Inc.
Company Website
Verastem
Company WebsiteBeyond their initial diagnosis, one of the worst things a patient with cancer can hear is that they have run out of options. At Verastem Oncology, we’re on a mission to make sure no patient ever has to hear that news. We embrace the power of partnership and collaboration to develop novel cancer therapies. It’s through these collaborations that we’ll bring hope to patients with RAS pathway-driven cancers. Purposeful. Unwavering. Influential. Insightful. Symbiotic. This is what drives us forward. Together, we look to see where an unexplored pathway will lead us.
Zentalis
Company WebsiteZentalis develops small molecule therapeutics with differentiated product profiles for a broad range of cancers.
Utilizing our Integrated Discovery Engine, the Company is developing a focused pipeline of potentially best-in-class oncology candidates, which include azenosertib, a WEE1 inhibitor for advanced solid tumors. The Company is also leveraging its extensive experience and capabilities across cancer biology and medicinal chemistry to advance its research on protein degraders. Zentalis has operations in San Diego.
Industry Collaboration Team
The ICT program was originally designed to develop, foster and facilitate a two-way communication channel between our pharmaceutical partners and the GOG Foundation, Inc. physician leadership. This was managed by setting up the opportunity to meet twice yearly at the NRG Semi-Annual Meetings for approximately (40) minutes.
As time progressed, the GOG further recognized the need for additional meetings to collaborate with our industry partners outside of formal clinical operations calls or advisory boards. The ICT program has since expanded to include more opportunities throughout the year in a formal setting. These opportunities allow our industry colleagues to focus on strategy, and engagement, while our team focuses on assuring that the right leaders are engaged to facilitate the important discussions needed. The GOG Foundation strives to build a strong partnership with Industry to serve as their research and collaborative partner, thus facilitating advancement in the field of gynecologic oncology.
This yearly membership opportunity as an ICT Platinum Member* provides:
- The opportunity to establish a two-way communication channel between Industry Partners and GOG that builds opportunities to communicate information about new and improving technologies, equipment, products, and services within gynecologic cancer research.
- Regular Business Strategy Meetings with GOG Leadership (up to four, (50) Fifty-minute meetings) throughout the year at major meetings (SGO Winter, SGO Annual, ASCO, WAGO, ESMO, ESGO, IGCS and (2) NRG/GOG Semi-Annual Meetings.)
- Coordination of face-to-face meetings or virtual meetings handled by GOG Staff, including the invitation process.
- A 60-minute face-to-face reception (2) times per year at the NRG/GOG Semi-Annual Meetings.
- Reduced meeting registration fees at the NRG Semi-Annual Meetings.
- Complimentary advertisement with link to website/webpage in GOG Foundation quarterly newsletter.
- Two (2) social media posts with advertisements on all of GOG Social Networks (Instagram, Facebook, Twitter, LinkedIn).
- Recognition on GOG’s website www.gog.org with company profile, logo, and direct link on website.
- Discounts on Advisory Board meetings, to not include physician FMV honoraria rate.
*Gold membership opportunities may not include all the items noted above. Please see ICT Description of Details for more information
To apply for ICT Membership, please click here to complete the application.
| Member Benefits | Platinum $50,000 | Gold $25,000 |
50 Minute Business Strategy Meetings with GOG Leadership:
|
Yes • Up to Four (4) Meetings Per year. |
Yes • Up to Two (2) Meetings Per year. |
Advisory Board Discounts
|
Yes • Platinum members will receive a 5% discount to host an advisory Board meeting at any of the following meetings: ASCO, ESMO, SGO, NRG, IGCS. |
No • Gold Level members can request an upgraded membership for an Ad Board |
Workshops
|
Yes • First five (5) to register are complimentary |
Yes • First two (2) to register are complimentary |
Symposium
|
Yes • First five (5) to register are complimentary |
No • No complimentary registrations |
Company Profile
|
Yes | Yes |
Company Logo
|
Yes |
No
|
Company Website
|
Yes | Yes |
Company Recognition
|
Yes
|
Yes
|
Reception & Dinner To Include ICT Members
|
Yes
|
Yes
|